From L-R: Co-founders Lucas Harrington, Trevor Martin, Ashley Tehranchi, Jennifer Doudna, Janice Chen (Mammoth)

Jen­nifer Doud­na's di­ag­nos­tic spin­out rais­es Mam­moth round as it ex­pands to ther­a­pies

When Mam­moth Bio­sciences launched out of CRISPR pi­o­neer Jen­nifer Doud­na’s lab in 2018, it did so with a bit of fan­fare but not a ton of cash.

Though the Se­ries A in­clud­ed promi­nent in­vestors such as Ap­ple CEO Tim Cook, it on­ly added up to $23 mil­lion, a small frac­tion of what some of the first gen­er­a­tion of CRISPR com­pa­nies had al­ready raised. They added $45 mil­lion in Jan­u­ary of 2020, the same month that Beam Ther­a­peu­tics, a CRISPR com­pa­ny launched around the same time, was putting the fin­ish­ing touch­es on a $180 mil­lion IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.